Cambiotics initiates first human clinical trial focused on PFAS reduction in firefighters with occupational PFAS exposure

Barchart · 1d ago

COPENHAGEN, Denmark, Nov. 3, 2026 /PRNewswire/ -- Cambiotics ApS ("Cambiotics"), the company developing beneficial bacteria designed to support the natural elimination of unwanted compounds, such as per- and polyfluoroalkyl substances (PFAS, known as "forever chemicals"), announced today that the first participant has been enrolled in its first human clinical trial investigating its proprietary probiotic strain, 46-SL1, as a dietary supplement in firefighters with occupational exposure to PFAS. The study is a 2 x 12-week randomised, double-blind, placebo-controlled crossover trial, and it is being conducted by Atlantia Clinical Trials in Chicago, Illinois [NCT07846371].

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.